Amylyx Pharmaceuticals, Inc. Detailed Financials
Full historical quarterly statements
| Metric | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | 0 | 0 | 0 | 0 | 0 | -665K | 416K | -1.0M |
| Cost of Goods Sold | 98K | 108K | 19.9M | 141K | 22.1M | 0 | 809K | 7.6M |
| Gross Profit | -98K | -108K | -19.9M | -141K | -22.1M | -665K | -393K | -8.6M |
| R&D Expenses | 27.6M | 21.1M | 19.9M | 27.1M | 22.1M | 22.9M | 21.2M | 23.1M |
| Operating Expenses | 43.8M | 36.5M | 16.2M | 42.7M | 15.7M | 40.0M | 75.3M | 44.8M |
| Operating Income | -43.8M | -36.6M | -36.0M | -42.9M | -37.8M | -40.7M | -75.7M | -53.4M |
| Other Income / Gains | 2.5M | 3.7M | 1.6M | 1.4M | 1.9M | 2.5M | 3.0M | -19.3M |
| Net Income | -41.3M | -33.0M | -34.4M | -41.4M | -35.9M | -37.5M | -72.7M | -72.7M |
| EPS (Diluted) | -0.37 | -0.28 | -0.37 | -0.46 | -0.42 | -0.55 | -1.07 | -1.07 |
| Reported Currency | USD | USD | USD | USD | USD | USD | USD | USD |
| Gross Profit Ratio | 0 | 0 | 0 | 0 | 0 | 1.00 | -0.945 | 8.455 |
| General And Administrative Expenses | 0 | 0 | 0 | 0 | 15.7M | 0 | 0 | 0 |
| Selling And Marketing Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Selling General And Administrative Expenses | 16.2M | 15.4M | 16.2M | 15.6M | 15.7M | 17.1M | 17.8M | 21.6M |
| Other Expenses | 0 | 0 | -19.9M | 0 | -22.1M | 0 | 36.2M | 0 |
| Cost And Expenses | 43.8M | 36.6M | 36.0M | 42.9M | 37.8M | 40.0M | 76.1M | 52.4M |
| Interest Income | 2.6M | 3.3M | 1.8M | 2.0M | 2.2M | 2.3M | 3.1M | 4.1M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation And Amortization | 98K | 108K | 120K | 141K | 156K | 160K | 221K | 208K |
| Ebitda | -41.2M | -30.9M | -34.3M | -41.3M | -35.8M | -38.0M | -72.5M | -72.5M |
| Ebitdaratio | 0 | 0 | 0 | 0 | — | 57.174 | -174.238 | 70.862 |
| Operating Income Ratio | 0 | 0 | 0 | 0 | — | 61.134 | -181.877 | 52.234 |
| Income Before Tax | -41.3M | -33.0M | -34.4M | -41.4M | -35.9M | -38.2M | -72.7M | -72.7M |
| Income Before Tax Ratio | 0 | 0 | 0 | 0 | — | 57.415 | -174.769 | 71.065 |
| Income Tax Expense | 0 | 46K | 0 | 0 | 0 | -635K | 0 | 0 |
| Net Income Ratio | 0 | 0 | 0 | 0 | — | 56.46 | -174.769 | 71.065 |
| Epsdiluted | -0.37 | -0.28 | -0.37 | -0.46 | -0.42 | -0.55 | -1.07 | -1.07 |
| Weighted Average Shs Out | 110.6M | 94.6M | 93.3M | 89.1M | 85.7M | 68.6M | 68.1M | 68.0M |
| Weighted Average Shs Out Dil | 110.6M | 94.6M | 93.3M | 89.1M | 85.7M | 68.6M | 68.1M | 68.0M |